Rights to antibody drug by China’s Keymed change hands in US acquisition
- Posted on March 24, 2026
- By South China Morning Post
- 9 Views
Rights to antibody drug by China’s Keymed change hands in US acquisition
Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.
